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Polymorphisms in the Interferon-/Interleukin-26 Gene Region
Contribute to Sex Bias in Susceptibility to Rheumatoid Arthritis
K. Vandenbroeck,1 S. Cunningham,1 A. Goris,2 I. Alloza,1 S. Heggarty,3 C. Graham,3
A. Bell,4 and M. Rooney4
Objective. To determine whether polymorphisms
in the interferon- (IFN)/interleukin-26 (IL-26; for-
merly, AK155) gene cluster contribute to sex-based
differential susceptibility to rheumatoid arthritis (RA).
Methods. Four microsatellite markers, located in
a 118-kb interval that contains both the IFN and IL-26
genes on chromosome 12q15, were typed in 251 patients
with RA and 198 unrelated healthy controls (all of whom
lived in Northern Ireland) by means of polymerase
chain reaction–based fragment analysis.
Results. Marker D12S2510, which is located 3 kb
3 from the IL-26 gene, was significantly associated with
RA in women (corrected P [Pcorr]  0.008, 2 degrees of
freedom [2 df]) but not in men (P  0.99, 2 df). A
3-marker haplotype, IFNGCA*13;D12S2510*8;
D12S2511*9, was inferred that showed significant un-
derrepresentation in women with RA (odds ratio 0.50,
95% confidence interval 0.32–0.78; P  0.002, Pcorr 
0.03) but not in men with RA.
Conclusion. Our results demonstrate that com-
mon polymorphisms in the IFN/IL-26 gene region may
contribute to sex bias in susceptibility to RA, by distort-
ing the propensity of female carriers versus male carri-
ers to contract this disease. These results conform to
our recent observations of a role for this gene cluster in
sex-based differential susceptibility to another Th1-type
inflammatory disease, multiple sclerosis.
Rheumatoid arthritis (RA) is a multifactorial
disease in which genetic factors are thought to account
for 60% of disease susceptibility (1). Current thinking
suggests a model in which the accumulated or epistatic
effects of multiple genes may predispose to RA. Genes
located in the HLA cluster have been consistently
confirmed as predisposing factors in RA, although this
region likely accounts for no more than one-third of the
total genetic component (1). One widely used approach
to the identification of additional susceptibility genes in
RA consists of association studies performed with poly-
morphic markers located within or near candidate genes
that are inferred from the etiopathogenesis of the dis-
order.
The interferon- (IFN) gene has recently at-
tracted attention for its role as a plausible candidate in
susceptibility to RA. This interest is generally based on
the observation that T cell clones established from RA
synovium typically produce Th1-related proinflamma-
tory cytokines, including IFN, but are deficient in the
production of Th2 cytokines (2). Different groups of
investigators have used a microsatellite polymorphism,
located in the first intron of this gene, as a marker to
assess the association of the IFN gene with susceptibil-
ity to, and the clinical course of, RA. An initial report by
Khani-Hanjani et al (3) claimed a strong association of
this marker with disease severity; however, this associa-
tion may have occurred erroneously because of the
misassignment of alleles (4,5). Indeed, further confirma-
tory studies failed to confirm the association between
the IFN gene polymorphism and RA susceptibility or
severity (6,7).
Notwithstanding these negative findings, indica-
tions that the IFN gene region has a role in determin-
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ing the differential susceptibility patterns of men and
women to RA justify further scrutiny. In a linkage study
on cytokine gene polymorphisms, linkage of borderline
significance with the IFN microsatellite was found in
male/male and female/male affected sibling pairs (loga-
rithm of odds score  0.96; P  0.03), but not in
female/female affected sibling pairs (8). Ollier reported
an odds ratio (OR) of 1.8 (95% confidence interval
[95% CI] 1.0–3.1) for single-nucleotide polymorphisms
in the IFN gene in men with RA (4).
An indication for a more general role of the IFN
gene region in sex-restricted differential susceptibility
patterns to inflammatory diseases comes from our re-
search on multiple sclerosis (MS). Like rheumatoid
arthritis, MS is a chronic inflammatory disease charac-
terized by endogenous production of Th1-type cyto-
kines, and epidemiologic surveys reveal a preponder-
ance of women affected by MS. We recently
demonstrated that the intronic microsatellite in the
IFN gene is differentially associated with MS in men
compared with women (9,10). We performed a linkage
disequilibrium screen and haplotype analysis of the
IFN region to narrow the interval for location of this
sex-associated factor (11). This allowed us to identify a
118-kb stretch that contains both the IFN and IL-26
genes (separated by 40 kb) as the most probable interval
for location of this factor (11). Although these initial
studies were performed in the Sardinian population, we
recently confirmed the occurrence of similar sex-
associated differences in this gene region in case–control
studies in the US and Northern Ireland (12).
In view of these findings, we were anxious to
verify whether the IFN/IL-26 gene region may contrib-
ute to sex bias in RA as well. In addition to the
microsatellite polymorphism in the IFN gene
(IFNGCA), we typed 3 other markers spanning the
118-kb sex-associated interval that emerged from our
MS study (11), i.e., D12S313, D12S2510, and D12S2511.
Typing and analysis were performed in a case–control
study of 250 Northern Irish patients with RA and 198
unrelated control subjects living in Northern Ireland.
The markers D12S2510 and D12S2511 were originally
identified and characterized in our laboratory and are
located at the IL-26 locus (13). We specifically inves-
tigated the association of individual markers and im-
puted haplotypes with RA, in patients stratified accord-
ing to sex.
PATIENTS AND METHODS
After informed consent was received, blood samples
were obtained from patients with RA who were seen by a
rheumatologist (MR) at Musgrave Park Hospital and Belfast
City Hospital. This study was approved by the ethics commit-
tee of Queen’s University. In order to recruit similar numbers
of men and women (in consideration of the increased preva-
lence of the disease in females), approximately every second
female patient and every male patient were prospectively
recruited. All patients were assessed by a rheumatologist, and
all fulfilled the American College of Rheumatology (formerly,
the American Rheumatism Association) criteria for RA (14).
A total of 251 patients (143 women and 108 men) were
recruited. The mean age of the patients was 57 years (range
23–82 years); the mean age of the female patients was 56 years
(range 25–81 years) and that of the male patients was 58 years
(range 23–82 years). The mean disease duration was 15 years
(range 1–56 years); the mean duration for female patients was
17 years (1–56 years) and that for male patients was 12 years
(range 1–37 years). All samples were coded at the source, in a
blinded manner. DNA samples were obtained from 198
healthy subjects (97 men and 101 women) at the Belfast City
Hospital and were used as a control. Both control subjects and
patients were of Northern Irish descent.
Polymorphic markers in the IFNG/IL26 gene region.
All DNA samples were typed for 4 distinct microsatellite
markers that span a 118-kb interval encompassing both the
IFNG and IL26 (previously called AK155) genes, i.e., from
centromere to telomere D12S313, IFNGCA, D12S2510, and
D12S2511. D12S313 is a multiallelic dinucleotide polymor-
phism located at a distance of 51 kb downstream from IFNG.
IFNGCA is a CA repeat polymorphism located in the first
intron of the IFN gene. D12S2510 and D12S2511 are novel
microsatellite polymorphisms in the IL-26 gene, discovered in
our laboratory (13). D12S2510 is a trinucleotide repeat poly-
morphism located 3 kb 3 to IL26, and D12S2511 is a penta-
nucleotide repeat polymorphism located in the third intron of
the IL-26 gene (13). D12S2510 consists of 2 frequent alleles
(137 bp and 143 bp, respectively) and a very rare 146-bp allele,
corresponding to 6, 8, and 9 repeat units, respectively. For
D12S2511, 3 frequent alleles of 175 bp, 180 bp, and 186 bp
corresponding to 8, 9, and 10 repeat units were found, together
accounting for 95% of the allele pool. Extreme care was
taken to ensure the correct assignment of alleles. Amplifica-
tion products were sequenced to determine the exact number
of repeats and were compared with reference samples. Alleles
of all markers are named according to the number of repeat
units, except D12S313, for which alleles are named according
to the length in basepairs.
Genotyping procedures. Details on primers and ampli-
fication procedures can be found online at The Genome
Database (www.gdb.org). Fragment analysis was performed by
electrophoresis through POP-6 polymer–filled capillaries on
an ABI Prism 3100 Sequencer with GeneScan software (Ap-
plied Biosystems, Foster City, CA). Forward primers were
labeled with fluorophores, and GeneScan 400 HD (Applied
Biosystems) was used as an internal size standard. In addition,
we used marker amplicons from an identical DNA pool
comprising 20 individual DNA samples as an internal control
on each run. Such a pool reflects both the frequencies and sizes
of all alleles present for each marker. Comparison of individual
samples with this control ensured consistent and correct allele
assignment.
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Statistical analysis. Rare alleles (frequency 5%)
were grouped together. The global and individual allele distri-
butions of each marker were compared between unstratified
and sex-stratified patients and controls by means of chi-square
analysis. Patients and controls were also compared for carrier,
homozygote, and heterozygote rates. Associations are also
expressed as ORs with logit 95% CIs. Maximum-likelihood
estimations of the haplotype frequencies were calculated with
an expectation-maximization algorithm implemented using
Arlequin software (available online at http://anthro.unige.ch/
arlequin). Frequent haplotypes (5%) were compared be-
tween patients and controls. P values are uncorrected. Cor-
rected P (Pcorr) values are Bonferroni-corrected for multiple
comparisons of genotypes, alleles, or haplotypes, and sex strata
per locus. Using the Arlequin software likelihood ratio, both
tests for pairs of markers in linkage disequilibrium and tests for
the population in Hardy-Weinberg equilibrium at individual
markers were applied.
RESULTS
The succession from centromere to telomere of
the markers typed in the present study is D12S313,
IFNGCA, D12S2510, and D12S2511 (with the latter 2
markers spanning the IL-26 locus), with spacing of
51 kb between D12S313 and IFNGCA, 40 kb between
IFNGCA and D12S2510, and 27 kb between D12S2510
and D12S2511 (11,13). Both the IFN and IL-26 genes
are transcriptionally oriented from telomere to centro-
mere (13). Table 1 summarizes the allele frequencies of
all 4 markers in RA patients and controls before and
after stratification according to sex.
In the unstratified group, only the marker
D12S2510 showed a weak global association with RA
(P  0.048, Pcorr not significant, 2 df). The global allele
distribution of marker D12S2510 was significantly differ-
ent in female RA patients compared with female con-
trols (P  0.004, Pcorr  0.008, 2 df) but not in male
patients versus male controls (P  0.99, 2 df). More
specifically, the frequency of the 6-repeat allele was
higher and that of the 8-repeat allele was lower in female
patients compared with female controls (Pcorr  0.006
and Pcorr  0.01, respectively). This is reflected in
significantly different rates of D12S2510*6/*6 homozy-
gotes (55.2% versus 32.7%; OR 2.54, 95% CI 1.50–4.32,
P  0.0004, Pcorr  0.002) and D12S2510*8 carriers
(44.1% versus 64.4%; OR 0.44, 95% CI 0.26–0.74, P 
0.002, Pcorr  0.01) in the female, but not male, patient–
control strata (Table 2).
With D12S2510 being de facto a biallelic marker,
Table 1. Allele frequencies of markers in the IFNG and IL26 gene region in patients and controls*
Marker, allele
Total Male Female
RA
(n  502)
Controls
(n  396)
RA
(n  216)
Controls
(n  194)
RA
(n  286)
Controls
(n  202)
D12S313
188 8.0 9.8 8.3 9.3 7.7 10.4
190 5.2 6.6 4.2 5.2 5.9 7.9
192 19.1 15.7 15.3 14.4 22.0 0.8
194 24.9 27.0 25.9 29.9 24.1 24.3
200 4.6 7.1 5.6 5.2 3.8 8.9
202 24.7 18.7† 26.4 19.1 23.4 18.3
204 5.2 5.6 5.1 5.7 5.2 5.4
X 8.4 9.6 9.3 11.2 7.4 8.0
IFNGCA
12 46.0 44.9 42.1 42.8 49.0 47.0
13 43.6 47.0 49.1 47.4 39.5 46.5
X 10.4 8.0 8.8 9.8 11.4 6.5
D12S2510
6 70.1 62.6† 65.3 65.5 73.8 59.9‡
8 29.1 35.9† 33.8 33.5 25.5 38.1§
X 0.8 1.5 0.9 1.0 0.7 2.0
D12S2511
8 20.9 21.0 20.4 23.2 21.3 18.8
9 57.8 60.4 58.8 58.2 57.0 62.4
10 16.5 14.9 16.2 13.4 16.8 16.3
X 4.8 3.9 4.7 5.1 4.8 2.5
* Values are the percentage of allele counts. X represents low-frequency alleles (occurring in 5% of total controls) grouped together. RA 
rheumatoid arthritis.
† P  0.03, corrected P (Pcorr)  0.05.
‡ P  0.001, Pcorr  0.006.
§ P  0.002, Pcorr  0.01.
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it is impossible to distinguish between either a primary
susceptibility effect of the 6/6 genotype (etiologic frac-
tion [EF] or attributable risk  0.34) or a primary
protective effect conferred by carriage of at least one
8-repeat allele (prevented fraction [PF]  0.36). Simi-
larly, the frequency of 6/6 homozygotes was significantly
higher (P  0.023, EF  0.24) and that of D12S2510*8
carriers lower (P  0.025, PF  0.26) in female patients
compared with male patients. It is worth noting that a
tendency for a difference in global allele distribution
(P  0.09) for underrepresentation of the 13 CA-repeat
allele of the IFN polymorphism (39.5% versus 46.5%;
P  0.12) and for a lower carriage rate for this allele
(60.8% versus 70.3%; P  0.13) was also seen in women
with RA compared with female controls, although these
associations were not significant at the 5% level (Tables
1 and 2). Neither the D12S313 nor the D12S2511
markers showed a sex-specific association with RA.
Except for a limited deviation caused by a smaller-than-
expected number of men heterozygous for one of the
rare alleles of IFNGCA, the control population was in
Hardy-Weinberg equilibrium for all markers.
In the total study population, linkage disequili-
brium between pairs of markers was found over the
whole 118-kb interval studied. Because linkage disequili-
brium with a disease/protective locus may be stronger
for haplotypes than for single alleles, 2-marker and
multiple-marker haplotype frequencies were estimated
by means of an expectation-maximization algorithm.
Several haplotypes were identified that were specifically
associated with RA in either male or female strata,
although none of these was associated with RA in the
unstratified group (Table 3, and data not shown). Of
these, the 3-marker haplotype IFNGCA*13;
D12S2510*8;D12S2511*9 was highly significantly under-
represented in women with RA (15.4% versus 26.6%;
OR 0.50, 95% CI 0.32–0.78, P  0.002). Even after
correction for 7 compared trimarker haplotypes in 2 sex
strata, this association remained significant (Pcorr 
0.03). This association was absent in the male patient–
control stratum.
DISCUSSION
We recently identified a 118-kb interval spanning
the IFN/IL-26 loci that is involved in male versus
female differential susceptibility to the inflammatory
disease MS (11). The present study was undertaken to
assess whether this interval is similarly associated with
another inflammatory disease, namely RA, in which
sex-specific susceptibility is also observed. Previous stud-
ies have indicated that polymorphisms at the IFN locus
show suggestive evidence for linkage and association
with RA in a sex-specific manner (4,8).
Table 2. Genotype distribution of IFNGCA and D12S2510 in patients with RA and controls, stratified by sex*
Locus, genotype
Male
P (Pcorr)
Female
P (Pcorr)
RA
(n  108)
Controls
(n  97)
RA
(n  143)
Controls
(n  101)
IFNGCA
Carrier 12 73 65 NS 101 73 NS
12/12 18 18 NS 39 22 NS
12/X 55 47 NS 62 51 NS
X/X 35 32 NS 42 28 NS
Carrier 13 81 69 NS 87 71 NS
13/13 25 23 NS 26 23 NS
13/X 56 46 NS 61 48 NS
X/X 27 28 NS 56 30 NS
D12S2510
Carrier 6 97 89 NS 132 88 NS
6/6 44 38 NS 79 33 0.0004 (0.002)†
6/X 53 51 NS 53 55 NS
X/X 11 8 NS 11 13 NS
Carrier 8 63 58 NS 63 65 0.002 (0.01)‡
8/8 10 7 NS 10 12 0.03 (NS)
8/X 53 51 NS 53 53 0.004 (0.02)
X/X 45 39 NS 80 36 NS
* Values are the number of subjects with each genotype. RA  rheumatoid arthritis; Pcorr  corrected P value; NS  not significant at the 5% level.
† Compared with subjects not homozygous for 6/6 (i.e., 6/X and X/X).
‡ Compared with noncarriers; this is a weighted average of the risk of homozygotes versus noncarriers and the risk of heterozygotes versus
noncarriers.
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Of the 4 markers tested in this interval, D12S2510
was individually associated with RA in women, but not
with RA in men. Importantly, the construction and
evaluation of 2- and 3-marker haplotypes reinforced
linkage disequilibrium with this putative sex-associated
locus. More specifically, 2- and 3-marker haplotypes
composed of allele combinations of IFNGCA*13,
D12S2510*8, and D12S2511*9 were significantly under-
represented in female patients with RA. It is worth
noting that the same haplotypes showed, identically,
underrepresentation in Northern Irish female patients
with MS versus female controls (Vandenbroeck K, et al:
unpublished observations). This finding is somehow in
contrast with previous studies on the IFN locus in RA,
in which the effects observed were stronger in male
patients (4,8). Remarkably, in our family-based study on
MS in Sardinian patients, we found a strong reduced
transmission of the haplotype IFNGCA*12;D12S2510*6
from heterozygous parents to male patients with MS,
with little evidence for association in female patients
(11). It is, however, likely that such discrepancies may be
at least partially explained by genetic differences be-
tween these study populations.
In the present study on RA, as well as in 2 MS
case–control studies (12), the IFNGCA*12 allele, the
D12S2510*6 allele, and the combination of the 2 alleles
in the haplotype IFNGCA*12;D12S2510*6, were less
frequent in male patients than in female patients,
whereas the inverse was true for alleles IFNGCA*13 and
D12S2510*8 and their haplotype IFNGCA*13;
D12S2510*8. These ratios were different from what was
seen in male versus female controls and were of similar
magnitudes in the 3 studies.
Pending further analysis, the present study indi-
cates that polymorphisms in the IFN/IL-26 gene region
are likely to be associated with susceptibility to auto-
immune diseases such as RA and MS in a sex-specific
manner. The single- and multiple-locus sex-specific as-
sociations with RA observed in the present study are
strongest for markers D12S2510 and D12S2511, both of
which are located at the IL-26 locus. Thus, the effects
seen previously (4,8) could possibly be attributable to
linkage disequilibrium with a sex-associated susceptibil-
ity locus that occurs closer to the IL-26 gene than to the
IFN gene. Typing of an extended number of RA
patients and controls for all markers analyzed in the
present study is warranted to confirm and refine the
present observations.
Ours is the first study to investigate the role of
the whole IFN/IL-26 gene region in susceptibility to
RA. A growing body of evidence suggests the presence
of a locus on chromosome 12q15 in proximity to the
IFN and IL-26 genes that is specifically involved in
sex-restricted patterns of susceptibility to inflammatory
diseases such as RA and MS (4,8,10–12). As a first step
toward the characterization of this locus, we have iden-
Table 3. Estimated haplotype frequencies for the most frequent haplotypes (5%) in sex-stratified RA patients and controls*
Haplotype
Male
P (Pcorr)
Female
P (Pcorr)
RA
(n  216)
Controls
(n  194)
RA
(n  286)
Controls
(n  202)
D12S313*192;IFNGCA*12 9.3 8.6 NS 17.5 10.1 0.02 (NS)
D12S313*194;IFNGCA*12 17.4 16.8 NS 12.2 10.7 NS
D12S313*202;IFNGCA*12 9.6 8.8 NS 7.8 7.8 NS
D12S313*188;IFNGCA*13 7.4 8.8 NS 6.1 6.8 NS
D12S313*194;IFNGCA*13 4.3 9.0 NS 9.5 12.2 NS
D12S313*202;IFNGCA*13 16.7 8.7 0.02 (NS) 13.7 9.5 NS
IFNGCA*12;D12S2510*6 39.8 39.4 NS 47.1 42.7 NS
IFNGCA*13;D12S2510*6 16.6 16.8 NS 15.7 11.6 NS
IFNGCA*13;D12S2510*8 31.5 29.6 NS 23.1 33.7 0.01 (NS)
D12S2510*6;D12S2511*8 15.7 17.4 NS 14.7 14.6 NS
D12S2510*6;D12S2511*9 35.5 34.6 NS 39.9 31.6 NS
D12S2510*6;D12S2511*10 11.0 10.3 NS 16.2 11.7 NS
D12S2510*8;D12S2511*9 23.2 23.0 NS 17.0 30.8 0.0004 (0.003)
IFNGCA*12;D12S2510*6;D12S2511*8 8.4 7.3 NS 6.9 8.3 NS
IFNGCA*12;D12S2510*6;D12S2511*9 20.6 23.5 NS 27.7 24.4 NS
IFNGCA*12;D12S2510*6;D12S2511*10 8.0 7.6 NS 11.1 8.0 NS
IFNGCA*13;D12S2510*6;D12S2511*8 2.7 6.0 NS 5.4 6.2 NS
IFNGCA*13;D12S2510*6;D12S2511*9 14.0 7.9 0.05 (NS) 6.3 4.6 NS
IFNGCA*13;D12S2510*8;D12S2511*8 6.9 6.3 NS 5.3 2.0 NS
IFNGCA*13;D12S2510*8;D12S2511*9 18.1 18.3 NS 15.4 26.6 0.002 (0.03)
* Values are the percentage. RA  rheumatoid arthritis; Pcorr  corrected P value; NS  not significant at the 5% level.
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tified a multiple-marker haplotype specifically associ-
ated with RA in women. Determining the genetics and
biology of this locus may profoundly increase our knowl-
edge of the mechanisms underlying sex bias in auto-
immune diseases and may have important implications
in terms of future strategies for therapeutic interven-
tions in RA.
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